Zentalis Beneish M Score

Stocks . USA . 
Stock . Zentalis PharmaceuticalsLlc
ZNTL Stock  USD 18.58  0.13  0.70%   
This module uses fundamental data of Zentalis PharmaceuticalsL to approximate the value of its Beneish M Score. Zentalis PharmaceuticalsL M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Zentalis PharmaceuticalsL Piotroski F Score and Zentalis PharmaceuticalsL Altman Z Score analysis.
  
The value of Total Debt is estimated to slide to about 41.3 M. The value of Debt Non Current is estimated to slide to about 41.3 M. Zentalis PharmaceuticalsL Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 8.86. Current Ratio is expected to rise to 8.48 this year, although the value of Earnings per Basic Share will most likely fall to (4.83) .
At this time, it appears that Zentalis PharmaceuticalsL is an unlikely manipulator. The earnings manipulation may begin if Zentalis PharmaceuticalsL's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Zentalis PharmaceuticalsL executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Zentalis PharmaceuticalsL's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.95
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables1.08Focus
Asset Quality1.23Focus
Expense Coverage0.83Focus
Gross Margin Strengs0.99Focus
Accruals Factor0.83Focus
Depreciation Resistance1.0Focus
Net Sales Growth0.99Focus
Financial Leverage Condition0.99Focus

Zentalis PharmaceuticalsL Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Zentalis PharmaceuticalsL's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Selling General and Administrative Expense45.2 M54.6 M
Significantly Down
Up
Slightly volatile
Revenues12.5 K12.6 K
Slightly Down
Down
Slightly volatile
Trade and Non Trade Receivables404.4 K375.3 K
Significantly Up
Down
Slightly volatile
Property Plant and Equipment Net54 M50.1 M
Significantly Up
Up
Slightly volatile
Liabilities Non Current52.5 M48.6 M
Significantly Up
Up
Slightly volatile
Current Liabilities47.2 M56.6 M
Fairly Down
Up
Slightly volatile
Total Liabilities85 M105.3 M
Significantly Down
Up
Slightly volatile
Investments Non Current23.5 M21.2 M
Significantly Up
Down
Slightly volatile
Investments Current392.4 M394.3 M
Slightly Down
Up
Slightly volatile
Investments414.9 M415.5 M
Slightly Down
Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Down
Slightly volatile
Depreciation Amortization and Accretion1.5 M1.4 M
Significantly Up
Up
Slightly volatile
Debt Non Current41.3 M45.2 M
Significantly Down
Up
Slightly volatile
Total Debt41.3 M45.2 M
Significantly Down
Up
Slightly volatile
Assets Non Current74.3 M87.4 M
Fairly Down
Up
Slightly volatile
Current Assets381.8 M451.9 M
Fairly Down
Up
Slightly volatile
Total Assets456.1 M539.3 M
Fairly Down
Up
Slightly volatile

Zentalis PharmaceuticalsL Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Zentalis PharmaceuticalsL's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Zentalis PharmaceuticalsL in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Zentalis PharmaceuticalsL's degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals

About Zentalis PharmaceuticalsL Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

1.54 Million

Zentalis PharmaceuticalsL Depreciation Amortization and Accretion is quite stable at the moment as compared to the past year. The company's current value of Depreciation Amortization and Accretion is estimated at 1.54 Million

About Zentalis PharmaceuticalsL Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Zentalis PharmaceuticalsLlc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zentalis PharmaceuticalsL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zentalis PharmaceuticalsLlc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Zentalis PharmaceuticalsL without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HEDJWisdomTree Europe Hedged
HEZUIShares Currency Hedged
COMDirexion Auspice Broad
Check out Zentalis PharmaceuticalsL Piotroski F Score and Zentalis PharmaceuticalsL Altman Z Score analysis. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for analysis

When running Zentalis PharmaceuticalsL price analysis, check to measure Zentalis PharmaceuticalsL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zentalis PharmaceuticalsL is operating at the current time. Most of Zentalis PharmaceuticalsL's value examination focuses on studying past and present price action to predict the probability of Zentalis PharmaceuticalsL's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zentalis PharmaceuticalsL's price. Additionally, you may evaluate how the addition of Zentalis PharmaceuticalsL to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Zentalis PharmaceuticalsL's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis PharmaceuticalsL. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis PharmaceuticalsL listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.99) 
Return On Assets
(0.29) 
Return On Equity
(0.59) 
The market value of Zentalis PharmaceuticalsL is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis PharmaceuticalsL's value that differs from its market value or its book value, called intrinsic value, which is Zentalis PharmaceuticalsL's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis PharmaceuticalsL's market value can be influenced by many factors that don't directly affect Zentalis PharmaceuticalsL's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Zentalis PharmaceuticalsL's value and its price as these two are different measures arrived at by different means. Investors typically determine Zentalis PharmaceuticalsL value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis PharmaceuticalsL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.


 
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY